|
Bayer moves ahead with the advancement of its comprehensive Radiology portfolio with progress on the development pipeline of new contrast agents as well as further partnerships in its digital business.
The company announced the presentation of new early clinical data for gadoquatrane, Bayer’s novel macrocyclic gadolinium-based compound currently in phase II development, at the Radiological Society of North America (RSNA) Annual Meeting. The 2022 RSNA will take place from November 27 to December 1 in Chicago, USA.
In addition, Bayer announced three collaboration agreements for its digital platform Calantic Digital Solutions as well as an AI accelerator program, reflecting the company’s commitment to driving innovations that benefit patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).
Bayer is making progress with its portfolio of contrast agents and injectors. The US submission of the MEDRAD Centargo CT injection system, the latest addition to Bayer’s computed tomography portfolio designed to simplify radiology workflows, is underway. In the area of contrast agents, gadoquatrane, Bayer’s novel macrocyclic gadolinium-based compound in phase II, is progressing in development. New early clinical data for gadoquatrane are being presented at this year’s RSNA:
Pharmacokinetics, Safety and Tolerability of a Novel Tetrameric, High Relaxivity, Macrocyclic Gadolinium-based Contrast Agent Gadoquatrane for CE-MRI -- Gadoquatrane features high stability as well as high relaxivity, which is a key property for use in contrast-enhanced magnetic resonance imaging, with the potential to enable a substantially lower gadolinium dose. The present study investigated its pharmacokinetics including excretion pathways, safety and tolerability in healthy volunteers.
On the occasion of RSNA 2022, Bayer also announced that it will partner with app developers Quantib, ClariPi, and EXINI Diagnostics to strategically expand the offering on its medical imaging platform Calantic Digital Solutions. The platform, which was launched recently, delivers access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer is broadening the already available options for thoracic and neurological diseases on the platform by including tools which aim to aid in breast and prostate imaging. With cancer and cardiovascular diseases on the rise, the demand for medical imaging to detect diseases, guide treatment decisions, and aid in therapy planning is growing. AI comes with the value proposition to support diagnosis and increase the throughput of medical imaging examinations.
In addition, Bayer has recently launched Calantic SPARK, a new accelerator program for medical imaging app developers to further foster innovation in radiology AI. The program will initially focus on North America and Europe and is planned to be expanded to other regions including Asia-Pacific. Bayer offers a targeted program to accelerate market readiness for early- and late-stage projects and offerings, providing advice spanning medical, regulatory, reimbursement expertise, and market access. Tapping the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK provides program participants with a potential pathway towards commercialization and distribution through Calantic Digital Solutions. Details about Calantic SPARK will be presented at Bayer’s booth as well as the AI Showcase Theatre at the RSNA.
Everyone deserves clear answers about their health, starting with an early and accurate diagnosis. As a true life science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence, from innovative products to high-quality services. Bayer has a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), devices for their precise administration, informatics solutions to support efficient and optimized patient care, as well as acknowledged educational programmes, that generated sales of 1.8 billion euros in 2021. In line with the company’s ambition to outperform the radiology market’s average annual growth of 5 percent by 2030, Bayer is strongly committed to research and development, which includes leveraging artificial intelligence and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction – from diagnosis to care.
|